You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification Name TRIAZOLOPYRIMIDINE Accession Number DB04669 Type Small Molecule Groups Experimental Description Not Available Structure Synonyms Not Available External Identifiers Not Available Approved Prescription Products Not Available Approved Generic Prescription Products Not Available Approved Over the Counter Products Not Available Unapproved/Other Products Not Available International Brands Not Available Brand mixtures Not Available Salts Not Available Categories Not Available UNII Not Available CAS number Not Available Weight Average: 382.237 Monoisotopic: 381.046332125 Chemical Formula C 17H 14BrN 6 InChI Key InChIKey=YWBFPKPWMSWWEA-UHFFFAOYSA-O InChI
Pharmacology Indication Not Available Structured Indications Not Available Pharmacodynamics Not Available Mechanism of action
Target Kind Pharmacological action Actions Organism UniProt ID Cyclin-dependent kinase 2 Protein unknown Not Available Human P24941 details Related Articles Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half life Not Available Clearance Not Available Toxicity Not Available Affected organisms Not Available Pathways Not Available SNP Mediated Effects Not Available SNP Mediated Adverse Drug Reactions Not Available Interactions Drug Interactions Not Available Food Interactions Not Available References Synthesis Reference
Nicole Bru-Magniez, Eric Nicolai, Jean-Marie Teulon, “Triazolopyrimidine derivatives which are angiotensin II receptor antagonists processes for preparing them and pharmaceutical compositions containing them.” U.S. Patent US5217973, issued March, 1964.
US5217973 General References Not Available External Links ATC Codes Not Available AHFS Codes Not Available PDB Entries Not Available FDA label Not Available MSDS Not Available ADMET Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9748 Blood Brain Barrier + 0.9455 Caco-2 permeable - 0.5096 P-glycoprotein substrate Non-substrate 0.6098 P-glycoprotein inhibitor I Non-inhibitor 0.8708 P-glycoprotein inhibitor II Non-inhibitor 0.5653 Renal organic cation transporter Non-inhibitor 0.6254 CYP450 2C9 substrate Non-substrate 0.8951 CYP450 2D6 substrate Non-substrate 0.8356 CYP450 3A4 substrate Non-substrate 0.574 CYP450 1A2 substrate Inhibitor 0.8209 CYP450 2C9 inhibitor Non-inhibitor 0.7096 CYP450 2D6 inhibitor Non-inhibitor 0.7801 CYP450 2C19 inhibitor Inhibitor 0.5374 CYP450 3A4 inhibitor Inhibitor 0.5 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8303 Ames test Non AMES toxic 0.6724 Carcinogenicity Non-carcinogens 0.8114 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.5969 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6942 hERG inhibition (predictor II) Non-inhibitor 0.6343
ADMET data is predicted using
, a free tool for evaluating chemical ADMET properties. (
Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Spectra Mass Spec (NIST) Not Available Spectra Not Available Taxonomy Classification Not classified Targets
comments powered by Disqus. comments powered by
Drug created on September 11, 2007 11:49 / Updated on August 17, 2016 12:24